S-1/A: Semnur Pharmaceuticals Updates Public Offering, Details SP-102 Progress

Semnur Pharmaceuticals files an S-1/A registration statement detailing its recent business combination, ongoing clinical development for its lead non-opioid pain candidate SP-102, and significant financial losses.

Summary

• Semnur Pharmaceuticals, Inc. (formerly Denali Capital Acquisition Corp.) completed a business combination on September 22, 2025, merging with Legacy Semnur Pharmaceuticals, Inc. (now Semnur, Inc.).
• The company is a late-stage clinical biopharmaceutical firm focused on non-opioid pain management, with its lead product candidate, SP-102 (SEMDEXA), targeting moderate to severe lumbosacral radicular pain (sciatica).
• SP-102 has received FDA fast track designation and, if approved, could be the first FDA-approved epidural steroid injection (ESI) for sciatica.
• A pivotal Phase 3 CLEAR-1 study for SP-102 was completed in March 2022, showing statistically significant and clinically meaningful improvement in pain and disability compared to placebo.
• However, the FDA requested a confirmatory Phase 3 CLEAR-2 trial for SP-102, which commenced in September 2025, due to risks associated with interventional procedures and the absence of existing FDA-approved ESIs for sciatica.
• The company incurred net losses of $154.3 million for the nine months ended September 30, 2025, and $4.7 million for the year ended December 31, 2024.
• As of September 30, 2025, cash and cash equivalents were $0.1 million, with an accumulated deficit of $269.6 million.
• The company is dependent on Scilex Holding Company for services and funding, and its recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern.
• Semnur is registering the issuance of up to 8,760,000 shares of common stock upon warrant exercise and the resale of up to 203,737,349 shares of common stock and 510,000 private warrants by selling securityholders.
• The company expects to receive up to approximately $100.74 million from the exercise of warrants, which will be used for working capital and general corporate purposes.
• Two securities purchase agreements (PIPE SPA and Biconomy SPA) for $20.0 million and $100.0 million, respectively, payable in Bitcoin for the latter, have not yet closed as of the prospectus date (December 19, 2025).

Sentiment

Score: 3

Explanation: The company faces severe liquidity issues, substantial accumulated losses, and significant doubt about its ability to continue as a going concern. While its lead product candidate, SP-102, shows promise and has FDA fast track designation, the FDA's requirement for an additional confirmatory Phase 3 trial and the pending closure of crucial financing agreements introduce considerable uncertainty and delays. The high general and administrative expenses for the nine months ended September 30, 2025, further exacerbate financial concerns.

Positives

• SP-102 has been granted fast track designation by the FDA, potentially expediting its development and review process.
• The completed pivotal Phase 3 CLEAR-1 study for SP-102 achieved primary and secondary endpoints, demonstrating statistically significant and clinically meaningful pain reduction and improved disability in sciatica patients.
• SP-102, if approved, has the potential to be the first FDA-approved epidural steroid product for sciatica, addressing a high unmet medical need and large market opportunity (estimated 4.8 million patients in the U.S. in 2024).
• The formulation of SP-102 is designed to be safer than currently used off-label ESIs, containing no neurotoxic preservatives, surfactants, solvents, or particulates, and is expected to be available in a pre-filled syringe.
• The company plans to leverage Scilex's established commercial infrastructure, including a sales force of over 70 representatives, for the commercialization of SP-102, aiming for a commercial launch in the second half of 2027.
• SP-102 benefits from a substantial intellectual property portfolio, including U.S. patents expiring in 2036, and technical barriers to entry for competitors.
• The management team has extensive experience in the biopharmaceutical industry, with a track record of product development and commercialization.

Negatives

• The company has incurred significant net losses since inception, with $154.3 million for the nine months ended September 30, 2025, and $4.7 million for the year ended December 31, 2024.
• As of September 30, 2025, the company had only $0.1 million in cash and cash equivalents and an accumulated deficit of $269.6 million.
• Recurring losses from operations, negative cash flows, and substantial cumulative net losses raise substantial doubt about the company's ability to continue as a going concern.
• The FDA requested a confirmatory Phase 3 CLEAR-2 trial for SP-102, indicating that the data from the single CLEAR-1 trial was not sufficient for approval, which will delay the NDA filing and potential commercial launch.
• The company is substantially dependent on the success of its single product candidate, SP-102, with no other products approved for commercial sale or revenue generated from product sales.
• The PIPE SPA ($20.0 million) and Biconomy SPA ($100.0 million, payable in Bitcoin) have not yet closed as of the prospectus date, creating uncertainty regarding anticipated funding.
• The company has identified material weaknesses in its internal control over financial reporting for the years ended December 31, 2023 and 2022, related to carve-out financial statements and stock-based compensation expense.
• The company relies on a sole or single-source supplier for sodium hyaluronate (an excipient for SP-102) and a single contract manufacturer (Lifecore) for SP-102, posing supply chain risks.
• Certain directors and officers have overlapping positions with Scilex, creating potential conflicts of interest.

Risks

• Incurring continued significant losses for the foreseeable future and potentially never achieving profitability.
• Inability to successfully complete clinical trials, obtain regulatory approvals, and commercialize SP-102 or any future product candidates in a timely manner or at all.
• Failure to establish satisfactory sales and marketing capabilities or secure third-party relationships for commercialization.
• Requirement for substantial additional funding, which may not be available on acceptable terms or at all, leading to potential delays or cessation of operations.
• Inability to generate sufficient cash to service indebtedness and other liquidity needs, potentially requiring alternative financing plans.
• Material weaknesses in internal control over financial reporting, which may lead to inaccurate financial reporting or material misstatements.
• Delays in clinical trials resulting in increased costs and delayed ability to obtain commercial approval and generate revenue.
• Regulatory approval for product candidates may be for a narrower indication than sought, or subject to significant limitations.
• Difficulty enrolling or maintaining patients in clinical trials, which could delay or prevent trial completion.
• Market opportunities for product candidates may be smaller than estimated, adversely affecting revenue and profitability.
• Significant competition from larger biotechnology and pharmaceutical companies with greater resources and experience.
• Failure to attain significant market acceptance of product candidates among physicians, patients, and healthcare payers.
• Uncertainty regarding third-party payor coverage and adequate reimbursement for newly approved products, potentially decreasing product revenue.
• Results of preclinical studies and early clinical trials may not be predictive of future clinical trial results, and interim data may change.
• Product candidates may cause undesirable side effects, delaying or preventing regulatory approval.
• Complex and difficult manufacturing processes for SP-102, potentially leading to delays or supply limitations.
• Inability to retain key executives, delaying development efforts and harming business.
• Challenges in managing company growth effectively, imposing strain on management and resources.
• Exposure to significant uninsured liabilities from product liability lawsuits.
• Disruption in research and development facilities due to natural or man-made disasters.
• Failure to realize anticipated benefits from future acquisitions, which can be costly and dilutive.
• Exposure to business, legal, regulatory, political, operational, financial, and economic risks associated with conducting business outside the United States.
• New risks and challenges from the increasing use of social media platforms, including potential non-compliance with regulations and adverse publicity.
• System failures, security breaches, or cyberattacks affecting computer systems, leading to data loss, reputational harm, or legal liability.
• Unstable market and economic conditions, including geopolitical conflicts, impacting financing and business strategy.
• Inability to maintain patent protection or if the scope of protection is not sufficiently broad, impairing competitive ability.
• Potential disputes over intellectual property rights that have been licensed, affecting licensing arrangements.
• Claims challenging inventorship or ownership of patents and other intellectual property.
• Claims of intellectual property infringement by third parties, leading to costly litigation or prevention of product sales.
• Inability to protect the confidentiality of trade secrets, harming business and competitive position.
• Changes in patent laws or jurisprudence diminishing the value of patents.
• Non-compliance with governmental patent agency requirements leading to loss of patent rights.
• Lengthy, time-consuming, and unpredictable regulatory approval processes by the FDA and comparable non-U.S. authorities.
• FDA not concluding that SP-102 satisfies Section 505(b)(2) pathway requirements, leading to longer, costlier, and riskier approval.
• Ongoing and continued regulatory requirements for approved products, resulting in significant expense and commercialization limitations.
• Fast track designation not necessarily leading to faster development or approval, or increasing likelihood of marketing approval.
• Changes in funding for the FDA, including government shutdowns, hindering timely product development or commercialization.
• Failure to comply with health and data protection laws and regulations, leading to enforcement actions, penalties, or litigation.
• Impact of new Trump administration actions, including executive orders, policies, new legislation, and judicial decisions, on business operations.
• Use of hazardous materials requiring compliance with environmental laws and regulations, which can be expensive and restrictive.
• Misconduct by employees, independent contractors, consultants, commercial partners, and vendors, leading to non-compliance and adverse effects.
• Subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, with potential for substantial penalties for non-compliance.
• FDA and other regulatory agencies actively enforcing laws prohibiting off-label promotion, leading to significant liability if violated.
• Healthcare reform measures hindering or preventing product candidates' commercial success.
• Inability to obtain prior FDA authorization for proposed product brand names, impacting commercialization.
• FDA and comparable foreign regulatory authorities not accepting data from clinical trials conducted outside the U.S.
• Highly volatile price of Bitcoin, impacting the company's operating results and share price if its cryptocurrency treasury strategy is implemented.
• The company's cryptocurrency treasury strategy has not been implemented or tested, and may prove unsuccessful.
• Classification of digital assets held as a security, leading to extensive regulation and significant costs or cessation of operations.
• Emergence or growth of other digital assets negatively impacting the price of cryptocurrencies held.
• Lack of legal recourse and insurance for digital assets increasing the risk of total loss in the event of theft or destruction.
• Irreversibility of digital asset transactions exposing the company to risks of theft, loss, and human error.
• Changes in accounting treatment of cryptocurrency holdings leading to significant accounting impacts and increased volatility.
• Custodially-held cryptocurrencies becoming part of custodians' insolvency estates in bankruptcy, leading to potential loss.
• Warrants may never be in the money and may expire worthless, and their terms may be amended adversely to holders.
• Redemption of unexpired warrants prior to exercise at a disadvantageous time for holders, making them worthless.
• Future sales, or the perception of future sales, of a substantial number of shares of Common Stock causing the price to decline.
• Fluctuations in operating results due to various factors, potentially causing stock price decline.
• Cash and cash equivalents adversely affected if financial institutions fail.
• Lack of research or adverse reports from securities analysts causing stock price and trading volume decline.
• Raising additional capital causing dilution to existing stockholders, restricting operations, or requiring relinquishment of product candidate rights.
• Principal stockholders, directors, and executive officers owning a significant percentage of capital stock, influencing management and potentially conflicting with public shareholders' interests.
• Limitations on the ability to use net operating loss and tax credit carryforwards due to ownership changes.
• Estimates or judgments relating to critical accounting policies proving incorrect, leading to operating results falling below expectations.
• Anti-takeover provisions in the Charter, Bylaws, and Delaware law making acquisitions more difficult.
• Exclusive forum provisions in the Charter limiting stockholders' ability to obtain a favorable judicial forum.
• Reduced reporting requirements as an emerging growth company making Common Stock less attractive to investors.
• Being a controlled company under Nasdaq Listing Rules, potentially relying on exemptions from corporate governance requirements.
• Increased costs and management time devoted to operating as a public company and complying with regulations.

Future Outlook

Semnur Pharmaceuticals anticipates continued significant expenses and operating losses for the foreseeable future as it advances SP-102 through clinical trials and seeks regulatory approval. The company targets a commercial launch of SP-102 in the second half of 2027, contingent on successful completion of the confirmatory Phase 3 CLEAR-2 trial by mid-2026 and subsequent FDA approval. Future liquidity will depend on existing cash, continued support from Scilex, and securing additional financing through various alternatives, including equity, debt, collaborations, or strategic transactions. The company aims to expand its product portfolio by developing or acquiring non-opioid assets and leveraging Scilex's commercial infrastructure.

Management Comments

• Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions.
• Through rigorous research and development, we believe we are on the cusp of establishing Semnur as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with its innovative and leading therapies.
• We believe that we have made substantial progress in demonstrating the rapid onset and enhanced tolerability of our product candidate.
• We expect to be able to complete the [CLEAR-2] trial by mid-2026 and submit our 505(b)(2) NDA to the FDA for approval. If approved, and given SP-102's fast-track designation, this would position us to achieve our targeted commercial launch of SP-102 in the second half of 2027.

Industry Context

Semnur Pharmaceuticals operates in the highly competitive and rapidly advancing biopharmaceutical industry, specifically targeting the non-opioid pain management market. This market is characterized by intense competition from larger biotechnology and pharmaceutical companies with greater resources. The company aims to address the significant unmet need for FDA-approved epidural steroid injections for sciatica, a condition affecting millions, and to provide an alternative to off-label ESI use and opioid pain medications. The increasing focus on non-opioid solutions due to the opioid crisis presents a favorable trend for Semnur's product candidate, SP-102, if it achieves regulatory approval and market acceptance.

Comparison to Industry Standards

• SP-102, if approved, has the potential to become the first FDA-approved epidural steroid product for the treatment of sciatica, differentiating it from currently used off-label particulate steroids (e.g., methylprednisolone acetate, triamcinolone acetonide, betamethasone sodium phosphate/acetate) which carry class warnings for serious neurologic complications.
• The Phase 3 CLEAR-1 trial results for SP-102 showed a group mean difference (mITT: 1.08-point difference; ITT: 0.52) and standardized effect size (mITT: 0.68; ITT: 0.28) for pain reduction, which were similar to or greater than those of other clinically meaningful analgesics for chronic low back pain (median group mean difference: 0.7-points; SES: 0.32) and off-label ESIs (median group mean difference: 0.49; SES: 0.29).
• SP-102's expected clinical benefit of up to approximately 100 days is anticipated to be longer than currently used off-label dexamethasone formulations, which pain specialists believe last for a short period.
• Unlike many existing products, SP-102 is formulated without neurotoxic preservatives, surfactants, suspensions, or particulates, aiming to improve tolerability and reduce risks associated with embolic events from inadvertent intra-arterial administration.
• The company's strategy to leverage the Section 505(b)(2) regulatory pathway for SP-102 aims to expedite development by relying on the FDA's prior findings for existing compounds, a common strategy for drug products with established mechanisms but improved formulations.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that would have a material adverse effect on its business.
• The company may become involved in various legal proceedings in the ordinary course of business, including employment, intellectual property, and product liability matters.

Related Party Transactions

• **Scilex Holding Company Relationship**: Legacy Semnur was a majority-owned subsidiary of Scilex prior to the Business Combination, and Scilex continues to beneficially own a significant percentage (approximately 82.07% of Common Stock and 100% of Series A Preferred Stock) of Semnur's outstanding voting stock post-combination.
• **Transition Services Agreement**: On September 22, 2025, Semnur entered into a Transition Services Agreement with Scilex, where Scilex will provide administrative, financial, legal, tax, insurance, facility, IT, R&D support, and commercialization support services for three years on a cost-plus-10% basis, with fees not exceeding $2.0 million per annum until the Oramed Note is repaid.
• **Sponsor Support Agreement**: On August 30, 2024, the Sponsor (Denali Capital Global Investments LLC) and Denali's directors/executive officers agreed to vote in favor of the Business Combination and against any competing proposals.
• **Company Stockholder Support Agreement**: On August 30, 2024, Scilex (as sole stockholder of Legacy Semnur) agreed to vote its shares in favor of the Merger Agreement and Business Combination.
• **Sponsor Interest Purchase Agreement (SIPA)**: On August 30, 2024, Scilex purchased 500,000 Denali Class B Ordinary Shares from the Sponsor for $2.0 million cash and 300,000 shares of Scilex common stock (adjusted to 8,571 shares after reverse stock split). The requirement to deliver Scilex shares was discharged on September 22, 2025.
• **Sponsor Promissory Notes**: Denali issued convertible promissory notes to the Sponsor (Sponsor Convertible Promissory Note and Sponsor Extension Convertible Promissory Note) totaling $1,523,237 outstanding as of March 31, 2025. These were settled on September 22, 2025, with $1,143,959.16 cash and a new promissory note for $806,366.78 (Sponsor Note).
• **Debt Exchange Agreement**: On August 30, 2024, Scilex and Semnur entered into an agreement to convert $54.2 million of outstanding indebtedness from Scilex to Semnur into 5,423,606 shares of Legacy Semnur Preferred Stock, which were then exchanged for 5,423,606 shares of Series A Preferred Stock and 542,361 shares of Common Stock at Closing.
• **Oramed Note**: On September 21, 2023, Scilex issued a $101.9 million senior secured promissory note to Oramed Pharmaceuticals Inc. (Oramed Note), due December 31, 2025. Semnur was initially a guarantor but was released from this obligation on September 22, 2025, upon completion of the Business Combination.
• **Consulting Services Agreement with 450W42ND MIMA, LLC**: On August 25, 2024, Legacy Semnur agreed to issue shares of Common Stock for consulting services. This agreement was terminated in September 2025, and no shares were issued.
• **Consulting Services Agreement with Wise Orient Investments Limited**: On August 26, 2024, Legacy Semnur agreed to issue 4,000,000 shares of Common Stock (post-Exchange Ratio adjustment) for consulting services, which were issued upon Closing.
• **Consulting Services Agreement with JW Investment Management Company Limited**: On June 12, 2025, Legacy Semnur agreed to issue 10,000,000 shares of Common Stock (post-Exchange Ratio adjustment) for advisory services, which were issued upon Closing. A 7% cash financing service fee is also contingent on successful PIPE contract facilitation.
• **Stock Issuance Agreement with Law Firm**: On July 22, 2025, Legacy Semnur issued 12,500,000 shares of Common Stock (post-Exchange Ratio adjustment) as a retainer for legal services and payment for prior services. These shares are held as collateral for current and future outstanding legal fees.

Stakeholder Impact

• **Shareholders**: Existing shareholders face significant dilution from the issuance of shares upon warrant exercise and the resale of shares by selling securityholders. The substantial net losses and going concern doubt pose a high risk to investment value. The concentration of voting power with Scilex and anti-takeover provisions limit the influence of public shareholders.
• **Employees**: The company has a small number of full-time employees and relies on Scilex employees and contractors. The new employment agreements for executive officers provide competitive compensation and change-in-control protections, but the overall financial instability could impact employee morale and retention.
• **Customers/Patients**: Patients suffering from sciatica could potentially benefit from SP-102 as a novel non-opioid treatment, if approved. Delays in regulatory approval mean delayed access to this potential therapy.
• **Creditors**: The company's significant indebtedness and going concern doubt pose risks to creditors, although some related party debt has been converted to equity. The Oramed Note's maturity extension indicates ongoing financial strain.
• **Suppliers/Manufacturers**: Reliance on single-source suppliers and manufacturers (e.g., Lifecore, Genzyme/Sanofi) creates dependency and risk of disruption, potentially impacting product development and commercialization.

Next Steps

• Complete the confirmatory Phase 3 CLEAR-2 trial for SP-102 by mid-2026.
• Submit a 505(b)(2) New Drug Application (NDA) to the FDA for SP-102 after the CLEAR-2 trial completion.
• Achieve targeted commercial launch of SP-102 in the second half of 2027, if regulatory approval is obtained.
• Secure additional financing through equity offerings, debt financings, collaborations, government contracts, or other strategic transactions to fund ongoing operations and development.
• Close the PIPE SPA for $20.0 million and the Biconomy SPA for $100.0 million (payable in Bitcoin) by December 31, 2025, or risk termination.
• Continue to implement remediation measures for identified material weaknesses in internal control over financial reporting.
• Identify and certify new suppliers for sodium hyaluronate to fulfill future supply requirements, as the previous agreement terminated.

Key Dates

Recommendation

Semnur Pharmaceuticals presents an extremely high-risk investment profile. The company is in a precarious financial position, evidenced by a critically low cash balance ($0.1 million), a massive accumulated deficit ($269.6 million), and recurring operating losses. The independent auditor has expressed substantial doubt about its ability to continue as a going concern. While its lead product candidate, SP-102, targets a large market and has FDA fast track designation, the FDA's requirement for an additional confirmatory Phase 3 trial introduces significant delays and increased costs, pushing potential commercialization further into the future. Crucial capital raises (PIPE SPA, Biconomy SPA) are pending and uncertain, and the company's reliance on related party funding and single-source suppliers adds to operational risks. The current market price of $20.00 for common stock appears disconnected from the severe financial distress and significant development hurdles. Given the profound financial instability, regulatory setbacks, and high execution risk, a seasoned investor would likely recommend a strong sell.

Keywords

Biopharmaceutical, Non-opioid pain management, SP-102, SEMDEXA, Sciatica, FDA Fast Track, Clinical trials, Phase 3, Epidural steroid injection, SEC filing, S-1/A, Business combination, Merger, Scilex Holding Company, Financial losses, Going concern, Capital raise, Warrants, Bitcoin, Intellectual property, Regulatory approval, Corporate governance